Pitolisant

• Narcolepsy
• Excessive Daytime Sleepiness
• Sleep Disorders

Pitolisant, marketed as Wakix, is a first-in-class histamine H3 receptor antagonist and inverse agonist used to treat excessive daytime sleepiness in adults with narcolepsy. It is also approved for cataplexy in narcolepsy. What sets pitolisant apart from older wake-promoting agents like modafinil and amphetamine-class stimulants is that it is not a controlled substance — the DEA reviewed its abuse potential and concluded scheduling was not warranted, an important practical advantage for patients facing chronic, lifelong therapy. Equally important, its mechanism is fundamentally different: rather than directly stimulating dopamine and norepinephrine release, pitolisant boosts wakefulness by amplifying endogenous histamine signaling in the brain.

Mechanism of Action

Histamine in the central nervous system is produced exclusively by neurons in the tuberomammillary nucleus of the posterior hypothalamus, which project widely to cortex, basal forebrain, brainstem, and spinal cord. Histaminergic firing is highest during active wakefulness, lower during quiet wakefulness, and essentially silent during REM sleep, marking histamine as a critical wake-promoting neurotransmitter. Histamine release is regulated in part by H3 autoreceptors located on the presynaptic terminals of histamine neurons themselves; activation of these autoreceptors inhibits further histamine release as a negative-feedback brake.

Pitolisant acts as a high-affinity, selective antagonist and inverse agonist at H3 receptors. By blocking the autoreceptor brake, it disinhibits histamine release, raising synaptic histamine concentrations in cortical and subcortical wake-promoting circuits. H3 receptors also serve as heteroreceptors on neurons releasing acetylcholine, norepinephrine, and dopamine, so pitolisant secondarily increases release of these neurotransmitters in mesocortical and prefrontal circuits — though without the direct release-promoting effect or reinforcing properties of amphetamines. The net result is improved wakefulness and, through histaminergic effects on REM-regulating brainstem nuclei, reduction in cataplectic attacks. The half-life is roughly 20 hours, supporting once-daily morning dosing. For broader context on the wake-sleep biology, our neurologic specialty overview is a useful starting point.

Clinical Use

Pitolisant is FDA-approved for excessive daytime sleepiness and for cataplexy in adult patients with narcolepsy. Phase 3 trials (HARMONY-1 and HARMONY-CTP) demonstrated significant reductions in Epworth Sleepiness Scale scores and weekly cataplexy attack rates compared with placebo, with effects sustained over open-label extensions. In current practice, modafinil and armodafinil typically remain first-line agents for excessive daytime sleepiness in narcolepsy because of cost and longer track records, but pitolisant is increasingly chosen earlier in patients with substance use history, those who require non-controlled options for occupational reasons (commercial drivers, pilots, military), or those who have not responded adequately to modafinil. For cataplexy specifically, pitolisant is one of three approved options alongside sodium oxybate and venlafaxine (off-label), and its non-controlled status is again attractive. Patients with narcolepsy benefit from a comprehensive treatment plan that includes scheduled naps, sleep hygiene, and treatment of comorbid sleep apnea or depression. The American Academy of Sleep Medicine provides updated narcolepsy treatment guidelines, and the NIH narcolepsy patient resource offers comprehensive patient-facing context.

How to Take It

Pitolisant is available as 4.45 mg and 17.8 mg tablets and is dosed once daily upon awakening. The titration schedule is gradual to limit insomnia and other early adverse effects: 8.9 mg (two 4.45 mg tablets) daily for the first week, 17.8 mg daily for the second week, and then up to 35.6 mg daily from week three forward based on response and tolerability. Tablets are swallowed whole with water and may be taken with or without food. Taking the dose later in the day risks insomnia because the pharmacokinetic effect persists into evening. If a dose is missed and the day is still early, it can be taken; if it is afternoon or later, the dose should be skipped and the schedule resumed the next morning. Effects on sleepiness usually emerge within the first one to two weeks, with full response sometimes taking up to eight weeks. Cataplexy reduction may follow a similar timeline. Patients should be counseled that the medication does not cure narcolepsy and that scheduled naps and sleep hygiene remain essential. Storage is room temperature, away from moisture.

Monitoring and Follow-Up

A baseline ECG with QTc measurement is essential before starting because pitolisant can prolong the QT interval; serum potassium and magnesium should be checked and corrected if low. ECG should be repeated after dose escalation in patients with cardiovascular disease or those taking other QT-prolonging medications. The Epworth Sleepiness Scale score, weekly cataplexy attack count, and a sleep diary all provide useful tracking metrics. Liver function tests are reasonable at baseline and periodically. Mood and psychiatric symptoms should be reviewed at each visit because anxiety, irritability, and rare worsening of depression can occur. Blood pressure and heart rate should be tracked. Because pitolisant induces CYP3A4 modestly, patients on hormonal contraceptives should be counseled to use additional non-hormonal contraception during therapy and for at least 21 days after discontinuation, since contraceptive failure has been reported. Reviewing your sleep and medication record at each visit, combined with an annual physical and our sleep apnea diagnosis guide when relevant, gives a clear picture of response.

Special Populations

In elderly patients, no formal dose adjustment is required but slower titration and lower target doses are reasonable given variable clearance. In moderate hepatic impairment (Child-Pugh B), the maximum dose is 17.8 mg daily; severe hepatic impairment (Child-Pugh C) is a contraindication. In severe renal impairment or end-stage renal disease, the maximum dose is also 17.8 mg daily. CYP2D6 poor metabolizers — roughly 6 to 10 percent of patients of European descent — have substantially higher exposure and should not exceed 17.8 mg daily; pharmacogenomic testing is not required but can be helpful when toxicity is suspected. Strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine) similarly raise exposure and trigger the same dose cap. Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine) lower exposure and may compromise efficacy. Pregnancy data are limited; animal studies showed embryo-fetal effects, and women of reproductive potential should weigh risk carefully. Lactation data are absent. Pediatric safety in narcolepsy was studied in the EAT-001 trial; pediatric labeling expansions are pending. Patients with congenital long QT syndrome or recent myocardial infarction should not use pitolisant.

When to Contact Your Doctor

Report syncope, palpitations, lightheadedness, or any sense of an irregular heartbeat — these may signal QT-related arrhythmia and warrant immediate evaluation with an ECG. New or worsening insomnia despite morning dosing, severe anxiety or agitation, hallucinations, or any thoughts of self-harm should prompt urgent contact. Patients on hormonal contraception who experience breakthrough bleeding or who become pregnant should reach out promptly. Worsening cataplexy or excessive sleepiness despite adherence may indicate dose adjustment is needed or that additional therapy should be considered. Severe nausea, persistent headache, or unexplained weight changes deserve attention. The MedlinePlus pitolisant page and the NIH narcolepsy resource provide patient-friendly background.

Practical Tips for Daily Use

Pitolisant is most effective when paired with structured behavioral strategies for narcolepsy. Take the dose immediately upon waking with a small glass of water, even before getting out of bed if you tend to forget once your morning routine begins. Scheduled brief naps (15 to 20 minutes) at consistent times — typically early afternoon and possibly mid-morning — substantially reduce sleepiness pressure regardless of what medication you are on. Maintain a regular sleep-wake schedule including weekends; irregular sleep amplifies daytime symptoms. Avoid alcohol, particularly in the evening, because it disrupts sleep architecture and worsens cataplexy. Caffeine is permitted but should be cut off by early afternoon to avoid interfering with the night's sleep. Track your Epworth Sleepiness Scale score monthly — it takes about 60 seconds and gives your prescriber far better data than a vague impression of how things are going. If you are on hormonal contraception, confirm with your prescriber the type and timing of supplemental non-hormonal contraception (typically a barrier method) needed for the duration of treatment plus 21 days. Inform employers, schools, or driving licensing authorities as legally required, and avoid driving when sleepy regardless of how much medication is on board.

Working With Your Care Team

Narcolepsy management is a marathon, and the right medication choice depends on your symptom mix, your other medications, and your work and lifestyle constraints. Schedule a visit with our team to discuss whether pitolisant fits your treatment plan and to coordinate the cardiovascular, psychiatric, and behavioral elements of comprehensive narcolepsy care.